No significant association were observed between NCL expression levels and both overall and disease-free survivals in the ER− PR+/− HER2− and ER+/− PR+/− HER2+ breast cancer subtypes (Figure 2A–D). This evidence concerns the gene NUCLEOLIN and breast carcinoma.